Generics The UK's Vectura Group saw its shares plummet as much as 20% (settling the day down around 18% at 52.75 pence) after it revealed that Swiss drug major Novartis' generics unit Sandoz had returned the US rights for the development and commercialization of VR315, its combination product for asthma/COPD. In Europe, there is no change to the agreement signed in April 2006, and Sandoz will continue to be fully responsible for the development, manufacture and commercialization of the product. 19 March 2010